Eloralintide: Lilly’s Amylin Peptide And Its Phase 2 Numbers

October 12, 2026

Eloralintide is Lilly’s investigational, once-weekly injectable amylin-analogue peptide, being studied as a potential treatment for obesity and related metabolic conditions. Formerly known as LY3841136, it is a selective amylin receptor agonist—not an approved medicine. Its clinical development has attracted attention because of substantial weight reductions reported in phase 2 research and subsequent findings from a combination study with tirzepatide.

The headline numbers are notable, but they need context. Early and mid-stage trials help researchers evaluate efficacy, tolerability and the questions that larger studies must answer. They do not establish that a treatment is suitable for routine use. Here is what Lilly’s reported eloralintide results show, what remains uncertain and why its amylin-based approach matters.

Understanding Eloralintide and Its Amylin-Based Approach

Eloralintide belongs to a category of investigational treatments designed around amylin biology. Amylin is a hormone involved in the regulation of eating and metabolic responses. An amylin-analogue peptide is designed to mimic aspects of that hormone’s activity, while a receptor agonist activates the receptors it targets.

Lilly describes eloralintide specifically as a selective amylin receptor agonist. That description distinguishes its mechanism from treatments focused on other hormone pathways. It also explains the interest in studying eloralintide both on its own and alongside another metabolic treatment.

However, a promising biological mechanism is not the same as a proven clinical benefit. The relevant questions are whether the compound produces reproducible results, whether participants can tolerate it and whether its overall benefit-risk profile supports regulatory approval. Eloralintide remains under investigation, and it is not FDA approved or available as an approved treatment.

Eloralintide Phase 2 Results: The Main Numbers

On 6 November 2025, Lilly announced results from its phase 2 eloralintide trial, identifying the findings with ObesityWeek and publication in The Lancet. The study, registered as NCT06230523, included 263 participants and followed treatment over 48 weeks. The reported mean baseline body weight was 109.1 kilograms.

Across four eloralintide treatment groups, reported weight reductions ranged from 9.5% to 20.1%. The placebo group recorded a 0.4% reduction. These figures describe trial results, not outcomes that an individual should expect.

Participants: 263.
Study duration: 48 weeks.
Mean baseline body weight: 109.1 kilograms.
Reported weight reductions across eloralintide groups: 9.5%, 12.4%, 17.6% and 20.1%.
Reported placebo weight reduction: 0.4%.

The clearest takeaway is the separation between the active-treatment groups and placebo within this study. Even so, the largest percentage should not be read as a universal expectation, a guaranteed outcome or definitive evidence of superiority over another medicine.

Why the 20.1% Figure Needs Context

The 20.1% result is likely to dominate discussions of eloralintide because it was the largest reported reduction in the phase 2 study. Yet a single headline percentage leaves out much of the information needed to assess a treatment.

Researchers also need to understand the variation between participants, treatment discontinuations, missing data, statistical methods and the durability of any observed changes. A group-level result does not mean every participant experienced the same outcome. Likewise, a 48-week study cannot answer every question about longer-term treatment.

Phase 2 findings are encouraging research signals, not confirmatory evidence. Their role includes informing the design of larger trials and identifying issues that need closer examination.

What the Trial Reported About Tolerability

Lilly’s phase 2 announcement described adverse events that included mild-to-moderate gastrointestinal effects and fatigue. Tolerability is an important part of interpreting the weight-change results, rather than a separate footnote.

A treatment’s potential value depends on more than the magnitude of an efficacy measure. Researchers must also assess how frequently adverse events occur, how disruptive they are and whether they affect participants’ ability to continue treatment.

The available summary should not be stretched into a claim that eloralintide is risk-free, broadly safe or suitable for a particular person. Larger studies are needed to characterize its safety profile more fully. The supplied findings also do not support precise claims about individual gastrointestinal symptoms or discontinuation rates.

Eloralintide Plus Tirzepatide: The Phase 2b Update

Eloralintide’s development extends beyond its use as a standalone investigational compound. On 30 September 2026, Lilly reported phase 2b findings at EASD for a combination of eloralintide and tirzepatide, referred to in the announcement as EloraTZP.

The study included 367 participants with type 2 diabetes. Lilly reported weight reduction of up to 23.3% with the combination, compared with 14.8% for tirzepatide alone. Reported A1C reductions were 2.9 percentage points with the combination and 2.4 percentage points with tirzepatide alone.

Study population: 367 participants with type 2 diabetes.
Combination weight reduction: up to 23.3%.
Tirzepatide-alone weight reduction: 14.8%.
Combination A1C reduction: 2.9 percentage points.
Tirzepatide-alone A1C reduction: 2.4 percentage points.

A1C reflects average blood glucose over time. A reduction expressed in percentage points describes a change in the A1C value; it should not be confused with a relative percentage reduction.

What the Combination Findings Do—and Do Not—Show

The phase 2b findings support continued investigation of the combination. Within the reported study, the combination produced larger changes in the stated weight and A1C measures than tirzepatide alone.

That does not establish the combination as an approved treatment or demonstrate that it is appropriate for every person with type 2 diabetes. Nor should its 23.3% figure be directly compared with the standalone trial’s 20.1% figure as though the studies were interchangeable.

The studies involved different research settings, and the combination trial specifically enrolled participants with type 2 diabetes. Cross-trial comparisons cannot substitute for a properly designed direct comparison.

Phase 3 ENLIGHTEN and the Approval Question

Lilly’s September 2026 update stated that phase 3 ENLIGHTEN was under way. This marks a further stage of clinical development, not a regulatory authorization.

Phase 3 research is intended to provide a more substantial evidence base for evaluating efficacy and safety. Important remaining questions include whether the earlier findings can be reproduced, how benefits and adverse events balance out and how results vary across the populations studied.

As of the supplied updates, eloralintide remains investigational. Readers should avoid interpreting descriptions such as promising, advanced or phase 3 as synonyms for approved. Regulatory decisions depend on the evidence submitted and its assessment, not simply on a compound reaching a later trial stage.

The Bottom Line on Eloralintide

Eloralintide has generated interest through a distinct amylin-based mechanism and notable phase 2 findings. Lilly reported weight reductions of up to 20.1% in its 48-week standalone study and up to 23.3% in a later phase 2b combination study with tirzepatide in participants with type 2 diabetes.

The essential distinction is between promising trial results and an established treatment. Eloralintide is not FDA approved, and its phase 2 data should not be presented as confirmatory. With ENLIGHTEN under way, the next stage of evidence will be important for assessing the compound’s potential role and limitations.

Sources

This article summarizes investigational research for informational purposes. It does not provide dosing instructions, treatment recommendations or medical advice.